Articles

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Clinica Universidad de Navarra, CIMA, Pamplona, Spain
Hematology & Oncology, Department of Medicine, University Hospital Tübingen, Germany
Vancouver General Hospital, Vancouver, BC, Canada
Department of Hematology, University Hospital Leuven, Belgium
Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Bénite, France
University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany
Hematology, University Hospital Hôtel-Dieu, Nantes, France
Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France
Institut Català d’Oncologia, HGTiP, Barcelona, Spain
Hôpital Saint Antoine, Paris, France
Bologna University School of Medicine, Institute of Hematology and Medical Oncology, Bologna, Italy
GUZ Moscow City Clinical Hospital S.P. Botkin, Russia
Hospital Universitario La Princesa, Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Princess Margaret Hospital, Toronto, ON, Canada
University Hospital Zurich, Switzerland
University of Calgary, Alberta, Canada
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Alexandra Hospital, Athens, Greece
Vol. 100 No. 10 (2015): October, 2015 https://doi.org/10.3324/haematol.2015.125864